구강회복응용과학지 (Journal of Dental Rehabilitation and Applied Science)

  • 제35권4호
  • /
  • Pages.199-205
  • /
  • 2019
  • /
  • 2384-4353(pISSN)
  • /
  • 2384-4272(eISSN)
대한턱관절교합학회 (Korean Academy of Stomatognathic Function and Occlusion)
권호 표지
DOI QR코드

DOI QR Code

치과임상에서 편두통 치료에 대한 제안

A proposal for management of migraine in dental clinic

  • 박연정 (연세대학교 치과대학 구강내과학교실) ;
  • 이혜진 (연세대학교 치과대학 구강내과학교실) ;
  • 김성택 (연세대학교 치과대학 구강내과학교실)
  • Park, YounJung (Department of Orofacial Pain and Oral Medicine, Yonsei University College of Dentistry) ;
  • Lee, Hye-Jin (Department of Orofacial Pain and Oral Medicine, Yonsei University College of Dentistry) ;
  • Kim, Seong Taek (Department of Orofacial Pain and Oral Medicine, Yonsei University College of Dentistry)
  • 투고 : 2019.09.10
  • 심사 : 2019.10.22
  • 발행 : 2019.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

흔한 중증 원발 두통 질환 중 하나인 편두통의 치료법에는 두통 일기 작성, 생활습관 개선, 운동 및 이완요법, 인지행동요법, 신경자극 등을 비롯한 비약물치료와 약물치료 등 다양한 전략이 있다. 본 종설은 이 중 약물 치료를 두통의 강도와 빈도에 기반하여 급성기치료와 예방치료로 나누어 고찰하고, 약물 치료의 효과를 극대화 시키기 위한 방법 및 편두통 치료의 최신 지견을 소개하고자 한다.

Management of migraine, one of common primary headache disorders, involves the diverse strategies non-pharmacological treatment, such as headache diary, lifestyle modification, regular exercise and relaxation, cognitive behavioral therapy and neurostimulation, and pharmacological treatment. Among the treatments, this review described a pharmacologic treatment of migraine, classified into acute and preventive treatment based on the severity and the frequency of headache. It introduced the way to optimize pharmacological treatment and updated the latest treatment for migraine.

키워드

참고문헌

  1. Lee TG CK, Chung KC, Choi JW. Prevalence of migraine in Korean adults: a nationwide survey. Korean J Headache 2000;1:57-66.
  2. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.
  3. Lee HJ, Kim YG, Kim ST. Diagnosis of headaches in dental clinic. J Dent Rehabil Appl Sci 2016;32:102-8. https://doi.org/10.14368/jdras.2016.32.2.102
  4. Kim BK, Cho SJ, Kim BS, Sohn JH, Kim SK, Cha MJ, Song TJ, Kim JM, Park JW, Chu MK, Park KY, Moon HS. Comprehensive Application of the International Classification of Headache Disorders Third Edition, Beta Version. J Korean Med Sci 2016;31:106-13. https://doi.org/10.3346/jkms.2016.31.1.106
  5. Brennum J, Brinck T, Schriver L, Wanscher B, Sorensen PS, Tfelt-Hansen P, Olesen J. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 1996;3:23-8. https://doi.org/10.1111/j.1468-1331.1996.tb00184.x
  6. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62. https://doi.org/10.1212/WNL.55.6.754
  7. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 2015;55:3-20. https://doi.org/10.1111/head.12499
  8. Laurell K, Artto V, Bendtsen L, Hagen K, Haggstrom J, Linde M, Soderstrom L, Tronvik E, Wessman M, Zwart JA, Kallela M. Premonitory symptoms in migraine: A cross-sectional study in 2714 persons. Cephalalgia 2016;36:951-9. https://doi.org/10.1177/0333102415620251
  9. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9. https://doi.org/10.1212/01.wnl.0000252808.97649.21
  10. Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the treatment of headache. Headache 2013;53 Suppl 2:54-61. https://doi.org/10.1111/head.12185
  11. Steiner TJ, Gobel H, Jensen R, Lampl C, Paemeleire K, Linde M, Braschinsky M, Mitsikostas D, Gil-Gouveia R, Katsarava Z; European Headache Federation and Lifting The Burden: the Global Campaign against Headache. Headache service quality: the role of specialized headache centres within structured headache services, and suggested standards and criteria as centres of excellence. J Headache Pain 2019;20:24. https://doi.org/10.1186/s10194-019-0970-7
  12. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001;56:S20-8. https://doi.org/10.1212/WNL.56.suppl_1.S20
  13. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidencebased guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45. https://doi.org/10.1212/WNL.0b013e3182535d20
  14. $BOTOX^{(R)}$ Chronic Migraine Reconstitution and Injection Workshop Guide. In: Allergan I, editor; 2010.
  15. Cefaly. Available from: https://www.cefaly.us/en/migraine-treatment-cefaly (Updated 2019 Sep 4).